Click me
Transcribed

Clinical Development Year in Review (2013)

2013 YEAR IN REVIEW ISR In 2013, R&D spending remained relatively flat and the number of studies started by industry also remained about the same, but outsourcing penetration is increasing. There are now more realistic options for sponsors seeking to outsource large studies. There will be more competition for large studies and the large CROS depend on large studies for their growth. reports CLINICAL DEVELOPMENT CRO CRO REVENUE & BACKLOG R&D AZ Restructures, To Build New HQ Forest Labs to Cut 9% of Workforce RESTRUCTURING Post-restructuring, Pfizer R&D focused on its top blockbuster prospects Quintiles, PAREXEL, Covance, ICON, and Charles River Revenue $24.03B Backlog Merck Announces Global Initiative to Novartis plots sales cuts in U.K. amid Sharpen Commercial and R&D Focus R&D restructuring $23.31 B $23.64 B Eisai slashes U.K. R&D jobs in 'global' restructuring $3.26B $3.22B $3.05B * CRO MERGERS & PARTNERSHIPS CRO Q1,2013 Q2,2013 Q3,2013 Based on ISR's market sizing model, we estimate that the top 5 CROS account for ~50% of the total market and the top 8 CROS account for -66% of the market. But overall, sponsors are not overly satisfied with the outsourcing models currently employed. Fewer than 6% of respondents are "completely satisfied" with their outsourcing. STOCK PRICES FARE OK • IHE (Pharmaceutical Industry Index Fund) is up 35% for the first 11 months of 2013 vs. the June 1st to December 1st 2013 A IHE is up 18% A DJIA is up 8% A Quintiles is up 1% PAREXEL is down 8% A ICON is up 13% •Covance is up 17% 2013 AQUISITIONS: PARTNERSHIPS: Dow Jones Industrial Average which is up "only" 24% over the same period KKR Quintiles PPD JLL Merck Serono Quintiles RPS Novella Acurian BioClinica CLINICAL TRIAL SUBMISSIONS PRA Corelab 392 Phase O Phase - Phase II - Phase III Phase IV l 326 338 $60.98 $57.8B 1st 3 Quarters of 2012 319 310 308 281 298 296 278 287 283 283 283 1st 3 Quarters of 2013 269 240 242 238 259 260 264 223 216 210 154 122 114 $17.48 $17.28 100 96 100 93 90 R&D SPENDING STAYS FLAT $1.6B $1.98 6. Pharma Biotech Generic Q4,2011 Q1, 2012 Q2,2012 03,2012 04,2012 Q12013 Q2,2013 03,2013 ISR Research www.fiercebiotech.com www.mercknewsroom.com ir.kker.com www.contractpharma.com online.wsj.com www.quintiles.com www.ppdi.com. www.bioclinica.com Bloomberg BusinessWeek www.google.com/finance www.clinicaltrials.gov Quintiles, PAREXEL Covance, ICON, and Charles River Quarterly Reports ISRreports.com| [email protected] | @aISRreports

Clinical Development Year in Review (2013)

shared by ISRreports on Dec 18
325 views
0 shares
0 comments
In 2013, R&D spending remained relatively flat and the number of studies started by industry also remained about the same, but outsourcing penetration is increasing. There are now more realistic optio...

Category

Health
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size